Australia’s medicinal cannabis firm, Althea Group becomes one of the first ever medical cannabis firms to enter the United Kingdom market to supply cannabis-based products for medicinal use (CBPM).
The launch of Althea UK comes in just after the NHS England allowed specialist doctors to make these products available to certain patients on prescription since November 2018.
Althea will initially supply CBPM in the UK in collaboration with global cannabis firm, Aphria, and hopes to begin the supply from March 2019.
The patients who are eligible to receive CBPM on prescription presently include the ones suffering from rare, serious kind of epilepsy, adults suffering from nausea, vomiting or muscle symptoms caused due to sclerosis. The list does not include chronic pain which is believed to be a major driver for cannabis medicinal use.
As per a recent study, CBPM can prove to be suitable for around 2.9 million patients in the UK.
Althea will also be unveiling a medical education platform to help specialist healthcare professionals access Althea products in the UK and will streamline the medicinal cannabis product prescription process for them as well.
Althea, which was founded in the year 2017 in Melbourne, is a leading CBPM supplier in Australia.